Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/183577
Title: Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy
Author: Goicoechea, Marian
Gomez Preciado, Francisco
Benito, Silvia
Torras Ambròs, Joan
Torra, Roser
Huerta, Ana
Restrepo, Alejandra
Ugalde, Jessica
Astudillo, Daniela Estefania
Agraz, Irene
Lopez Mendoza, Manuel
Arriba, Gabriel de
Corchete, Elena
Quiroga, Borja
Gutierrez, Maria Jose
Martin Conde, Maria Luisa
Lopes, Vanessa
Ramos, Carmela
Mendez, Irene
Cao, Mercedes
Dominguez, Fernando
Ortiz, Alberto
Spanish Group for the Study of Glomerular Diseases (GLOSEN)
Keywords: Malalties del ronyó
Malaltia de Fabry
Assaigs clínics
Enzims
Kidney diseases
Fabry's disease
Clinical trials
Enzymes
Issue Date: 10-Mar-2021
Publisher: Elsevier España
Abstract: Fabry disease may be treated by enzyme replacement therapy (ERT), but the impact of chronic kidney disease (CKD) on the response to therapy remains unclear. The aim of the present study was to analyse the incidence and predictors of clinical events in patients on ERT. Study design: Multicentre retrospective observational analysis of patients diagnosed and treated with ERT for Fabry disease. The primary outcome was the first renal, neurological or cardiological events or death during a follow-up of 60 months (24-120). Results: In 69 patients (42 males, 27 females, mean age 44.6±13.7 years), at the end of follow-up, eGFR and the left ventricular septum thickness remained stable and the urinary albumin: creatinine ratio tended to decrease, but this decrease only approached significance in patients on agalsidase-beta (242-128mg/g (p=0.05). At the end of follow-up, 21 (30%) patients had suffered an incident clinical event: 6 renal, 2 neurological and 13 cardiological (including 3 deaths). Events were more frequent in patients with baseline eGFR≤60ml/min/1.73m2 (log Rank 12.423, p=0.001), and this remained significant even after excluding incident renal events (log Rank 4.086, p=0.043) and in males and in females. Lower baseline eGFR was associated with a 3- to 7-fold increase the risk of clinical events in different Cox models. Conclusions: GFR at the initiation of ERT is the main predictor of clinical events, both in males and in females, suggesting that start of ERT prior to the development of CKD is associated with better outcomes.
Note: Reproducció del document publicat a: https://doi.org/10.1016/j.nefro.2021.01.002
It is part of: Nefrología, 2021, vol. 41, num. 6, p. 652-660
URI: http://hdl.handle.net/2445/183577
Related resource: https://doi.org/10.1016/j.nefro.2021.01.002
ISSN: 0211-6995
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
716082.pdf842.98 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons